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• Serogroup A cases ↓ 
• Serogroup W and X  
still causing epidemics 
► NO AFFORDABLE  
VACCINE FOR ALL SEROGROUP AVAILABLE 
African meningits Belt 
• >350 million people at risk 
• Incidence up to 1000 per 
100,000 people  
• Mortality up to 15% of 
cases 
Generalised Modules  
                 for Membrane Antigens 
Gram-negative bacteria naturally shed outer 
membrane vesicles (OMVs). Structural changes in 
bacterial outer membrane lead to GMMA, 
Generalized Modules for Membrane Antigens: 
outer membrane vesicles to use as vaccine. 
They are safe, cheap to produce, and can give 
broad protection against pathogens. 
We genetically engeneered a N. meningitidis 
african strain: it overproduces GMMA containing 
protective antigens against meningoccocal strains 
affecfcting Sub-Saharan Africa.  
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Detoxified endotoxin 
NO capsule 
Over-expressing protective antigens 
Over blebbing 
100nm 
Negative Stain Transmission Electron Microscopy of 
engineered N. meningitidis 
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• We genetically engineered an African meningoccocal strain with deleted capsule biosynthesis, 
detoxified endotoxin, over-expression of protective antigens, and over-blebbing. 
• GMMA from this mutated strain are promising as an affordable vaccine against all N. 
meningitidis serogroups causing meningococcal disease in sub- Saharan Africa. 
• Evalution of fine-specificity of protection and mechanism of cellular immunuty to the vaccine are 
under evaluation. 
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